ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

439
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
bullishZJLD Group
26 Jan 2023 10:31

ZJLD Group Pre-IPO Tearsheet

ZJLD Group (ZJLD HK) is looking to raise up to US$400m in its Hong Kong IPO. The deal will be run by Goldman Sachs and China Securities.

Logo
590 Views
Share
26 Jan 2023 08:05

Hong Kong Connect Flows (Jan 20th): China Mobile, Tencent, Meituan, CCB, HKEX

We analyzed southbound Hong Kong connect flows in the past week and highlight flows for China Mobile, Tencent, Meituan, China Construction Bank,...

Logo
296 Views
Share
bullishMankind Pharma
25 Jan 2023 10:05

Mankind Pharma Pre-IPO - The Positives - Diverse Portfolio with Steady past Performance

Mankind Pharma  is looking to raise about US$1bn in its upcoming India IPO. In this note, we talk about the positive aspects of the deal.

Logo
383 Views
Share
20 Jan 2023 11:25

ECM Weekly (20th Jan 23) - HK Brokers, Wuxi, IQIYI, Anycol, Adani, WM Mot, LG Ene, AIn, Oasis, Perta

Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.

Logo
502 Views
Share
bearishOASIS /Korea
18 Jan 2023 09:00

Oasis Corporation IPO - Sole Profitable Player but Maybe Not for Long

OASIS Corp (1799513D KS) is looking to raise up to US$166m in its upcoming Korea IPO. Oasis Corporation is an early morning delivery service...

Logo
Ethan Aw
369 Views
Share
x